此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies (PSYGEN)

2026年6月30日 更新者:Centre Hospitalier Universitaire Dijon

According to the World Health Organization, one in eight people worldwide has a mental disorder, defined as a significant impairment in thinking, emotional regulation, or behavior. These disorders are classified according to the DSM-5. These psychiatric disorders may be atypical in terms of their age of onset, course of the illness, unusual response to treatment, or classification (significant impact but classified as a "disorder not otherwise specified" by the DSM-5). These disorders can occur sporadically or run in families.

In France, there are no genetic testing recommendations for these patients. A CGH-array analysis may be ordered as part of patient care, as may testing for Fragile X syndrome, depending on the clinical context.

The main hypothesis is that atypical psychiatric disorders result from multifactorial inheritance, involving a combination of common genetic variations and environmental factors. Pangenomic association studies and twin studies have already demonstrated heritability in these psychiatric disorders. It has now been shown that some neurodevelopmental disorders (NDDs) and psychiatric disorders-such as autism spectrum disorders or schizophrenia, for which similar hypotheses were proposed in the past-may result from monogenic inheritance. Furthermore, preliminary indications now allow for the prescription of genome sequencing on the platforms of the France Genomic Medicine Plan 2025.

To date, no study has evaluated the role of high-throughput sequencing in an etiological approach to atypical, non-syndromic psychiatric disorders. Through this study, we aim to assess whether genome sequencing (GS) could be relevant for atypical, non-syndromic psychiatric disorders, which would be the case if it leads to an etiological diagnosis in at least 12% of cases.

The establishment of the GénoPsy network (Centers of Excellence for Behavioral Disorders in Developmental Disorders) creates an environment that is highly conducive to the development of this project.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

255

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

取样方法

非概率样本

研究人群

The index case and his two parents

描述

Inclusion Criteria:

  • Index case with one or more psychiatric disorders confirmed by a psychiatrist and/or child psychiatrist, whose evaluations may be supplemented as needed as part of their care, and who meets at least ONE of the following criteria for atypicality:
  • Early age of onset
  • Unusual course of the disorder (polymorphic/fluctuating)
  • Treatment resistance
  • Disorder classified as "unspecified" by the DSM-5 with significant functional impact
  • Index case aged 3 to 50 years, inclusive
  • Consent signed by the biological parents and by the "index case, if of legal age"
  • Index case and their parents enrolled in or eligible for a social security program
  • Sample collection possible from the index case and their two known biological parents

Exclusion Criteria:

  • Genetic testing previously performed (CGH array, targeted gene testing, gene panel, etc.)
  • Parent(s) and/or the index case subject to a court-ordered protective measure
  • The index case and his or her parents have a condition that, in the investigator's opinion, would contraindicate the subject's participation in the study
  • Presence of an intellectual developmental disorder confirmed by a neuropsychological test or strongly suspected clinically in the index case and/or their parents
  • Index case with a clear syndromic diagnosis
  • Index case with a psychiatric disorder already covered by a pre-indication under PFMG2025.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
The index case and his two parents
Index cases with one or more psychiatric disorders
Collection of an EDTA blood sample from the index case and his or her two biological parents

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Identification of at least one likely pathogenic or pathogenic variant (ACMG classification class 4/5) responsible for a condition that explains the patient(s psychiatric symptoms.
大体时间:8 months
8 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2029年5月1日

研究完成 (估计的)

2029年5月1日

研究注册日期

首次提交

2026年6月30日

首先提交符合 QC 标准的

2026年6月30日

首次发布 (实际的)

2026年7月7日

研究记录更新

最后更新发布 (实际的)

2026年7月7日

上次提交的符合 QC 标准的更新

2026年6月30日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅